

Next Generation Tissue Biomarkers Market Size, Share and Growth Outlook 2026: By Product Type, By Biomarker Type, By Technology, By Application, By End Use, Companies to 2034

<https://marketpublishers.com/r/N439037F3AB4EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: N439037F3AB4EN

Abstracts

The global Next Generation Tissue Biomarkers Market size is forecast to increase from \$3.93 Billion in 2026 to \$10.57 Billion in 2034 at a CAGR of 13.16% between 2026 and 2034.

The Next Generation Tissue Biomarkers market report provides detailed analysis and outlook of Next Generation Tissue Biomarkers segments including By Product Type (Reagents and Assays, Instruments and Platforms, Software and AI Analysis Solutions), By Biomarker Type (Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers), By Technology (Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), Mass Spectrometry (MS)-based Proteomics, Spatial Biology Platforms, Digital Pathology and AI Image Analysis), By Application (Oncology, Companion Diagnostics, Drug Discovery and Development, Neurology, Cardiovascular and Infectious Diseases), By End Use (Hospitals and Reference Labs, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs)) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Next Generation Tissue Biomarkers Industry Overview

Multi-Omics Technologies, Artificial Intelligence, and Spatial Molecular Profiling Are Driving the Next Generation Tissue Biomarkers Market

The next generation tissue biomarkers industry is undergoing rapid transformation as advances in proteomics, genomics, epigenomics, artificial intelligence, and spatial biology technologies enable increasingly precise characterization of disease mechanisms and therapeutic responses. Pharmaceutical companies, diagnostic developers, and research institutions are investing heavily in next-generation biomarker platforms capable of extracting clinically actionable insights from complex tissue samples. The growing adoption of multimodal molecular profiling, artificial intelligence-based predictive analytics, and high-throughput omics technologies is accelerating biomarker discovery across oncology, immunology, neurology, and precision medicine applications. These developments are reshaping tissue diagnostics by moving beyond conventional histopathology toward highly integrated molecular characterization platforms.

Advanced Proteomics and AI-Driven Analytics Are Expanding Biomarker Discovery Capabilities

A major trend driving the next generation tissue biomarkers market is the convergence of deep proteomics and artificial intelligence technologies to identify clinically relevant molecular signatures. Reflecting this trend, Biognosys introduced updated versions of its Spectronaut 21 and SpectroMine 6 software platforms at the American Society for Mass Spectrometry conference, enhancing the sensitivity and throughput of deep proteomic analyses performed on formalin-fixed paraffin-embedded (FFPE) tissue specimens. These advancements support the discovery of novel biomarkers from archived clinical samples that have historically been challenging to analyze. Similarly, Tempus AI expanded the clinical application of tissue biomarkers through the launch of its Immune Profile Score (IPS), an artificial intelligence-driven prognostic platform that analyzes molecular tissue data to predict immunotherapy responses in stage IV and metastatic pan-solid tumors.

Epigenomic and Multi-Omics Technologies Are Unlocking Previously Uncharacterized Biomarkers

The next generation tissue biomarkers industry is also being transformed by emerging multi-omics technologies capable of simultaneously interrogating multiple molecular dimensions within tissue samples. Supporting this evolution, Alida Biosciences launched its EpiPlex platform, enabling simultaneous detection and quantification of multiple RNA modifications using short-read sequencing technologies. This capability provides researchers with access to previously difficult-to-characterize epigenomic

biomarkers and facilitates deeper understanding of disease biology, therapeutic response mechanisms, and molecular heterogeneity. The integration of proteomics, transcriptomics, epigenomics, and artificial intelligence-based analytics is accelerating the transition toward comprehensive tissue biomarker ecosystems capable of supporting next-generation precision medicine and targeted therapeutic development.

Next Generation Tissue Biomarkers Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Next Generation Tissue Biomarkers market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., Illumina, Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Akoya Biosciences, Inc. (Quanterix Corporation), Bio-Techne Corporation. The Next Generation Tissue Biomarkers market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Next Generation Tissue Biomarkers industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Next Generation Tissue Biomarkers Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Next Generation Tissue Biomarkers companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Next Generation Tissue Biomarkers markets

- Competitive analysis including business description, product analysis, and

financial profiles

Key country specific analysis detailing key factors shaping the short-term and long-term outlook

Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Next Generation Tissue Biomarkers Market Competitive Benchmarking and Company Analysis

Leading companies in Next Generation Tissue Biomarkers industry include- F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., Illumina, Inc., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Akoya Biosciences, Inc. (Quanterix Corporation), Bio-Techne Corporation. The Next Generation Tissue Biomarkers market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Next Generation Tissue Biomarkers Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Next Generation Tissue Biomarkers market remains one of the strongest-performing segments in the country.

The US Next Generation Tissue Biomarkers Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Next Generation

Tissue Biomarkers market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Next Generation Tissue Biomarkers industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Next Generation Tissue Biomarkers markets

Canada's strong Next Generation Tissue Biomarkers sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Next Generation Tissue Biomarkers market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Next Generation Tissue Biomarkers Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Next Generation Tissue Biomarkers market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Next Generation Tissue Biomarkers population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Next Generation Tissue Biomarkers industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Next Generation Tissue Biomarkers market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Next

Generation Tissue Biomarkers sales through 2034

France Next Generation Tissue Biomarkers companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Next Generation Tissue Biomarkers Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Next Generation Tissue Biomarkers distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Next Generation Tissue Biomarkers Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Next Generation Tissue Biomarkers market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Next Generation Tissue Biomarkers industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product

launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Next Generation Tissue Biomarkers industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Next Generation Tissue Biomarkers Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Next Generation Tissue Biomarkers market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Next Generation Tissue Biomarkers market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Next Generation Tissue Biomarkers Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500

million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending.

Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Next Generation Tissue Biomarkers Market Segmentation

By Product Type

Reagents and Assays

Instruments and Platforms

Software and AI Analysis Solutions

By Biomarker Type

Genomic Biomarkers

Proteomic Biomarkers

Epigenetic Biomarkers

Transcriptomic Biomarkers

Metabolomic Biomarkers

By Technology

Next-Generation Sequencing (NGS)

Immunohistochemistry (IHC)

Mass Spectrometry (MS)-based Proteomics

Spatial Biology Platforms

Digital Pathology and AI Image Analysis

By Application

Oncology

Companion Diagnostics

Drug Discovery and Development

Neurology

Cardiovascular and Infectious Diseases

By End Use

Hospitals and Reference Labs

Pharmaceutical and Biotechnology Companies

Academic and Research Institutes

Contract Research Organizations (CROs)

Leading Companies in Next Generation Tissue Biomarkers Industry (2026)

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.

Agilent Technologies Inc.

QIAGEN N.V.

Bio-Rad Laboratories Inc.

Illumina, Inc.

Laboratory Corporation of America Holdings (Labcorp)

Quest Diagnostics Incorporated

Akoya Biosciences, Inc. (Quanterix Corporation)

Bio-Techne Corporation

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the
Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market
developments

Make trusted decisions building on our 10-year experience in developing reports
on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Next Generation Tissue Biomarkers Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Next Generation Tissue Biomarkers Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL NEXT GENERATION TISSUE BIOMARKERS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Next Generation Tissue Biomarkers Markets in 2026
- 3.2. Global Historic and Forecast Next Generation Tissue Biomarkers Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics

- 3.4.1. Key Next Generation Tissue Biomarkers Market Driving Forces and Their Impact on Market Outlook
- 3.4.2. Short and Long-Term Trends and Insights Shaping the Future
- 3.4.3. Potential Next Generation Tissue Biomarkers Market Opportunities for Industry Stakeholders
- 3.4.4. Potential Challenges across Next Generation Tissue Biomarkers Value Chain

CHAPTER 4- NEXT GENERATION TISSUE BIOMARKERS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

- 4.1. Porter's Five Forces Analysis
 - 4.1.1. Bargaining Power of Buyers
 - 4.1.2. Bargaining Power of Suppliers
 - 4.1.3. Threat of Substitutes
 - 4.1.4. Threat of New Entrants
 - 4.1.5. Intensity of Competitive Rivalry
 - 4.1.6. Market Attractiveness Analysis by Segment
 - 4.1.7. Market Attractiveness Analysis by Region
- 4.2. Competitive Landscape
 - 4.2.1 Market Share Analysis of Leading Next Generation Tissue Biomarkers Companies
 - 4.2.2 Recent Strategic Developments
 - 4.2.3 Mergers, Acquisitions, and Partnerships
 - 4.2.4 Product Launches and Innovation Trends
 - 4.2.5 Key Success Factors
- 4.3. Value Chain Analysis
 - 4.3.1. Key Value Chain Segments
 - 4.3.2. Dominant players by value-chain stage
- 4.4. SWOT Analysis
 - 4.4.1. Key Strengths and Opportunities
 - 4.4.2. Major Weaknesses and Threats
- 4.5 Technology Roadmap
- 4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- NEXT GENERATION TISSUE BIOMARKERS MARKET OUTLOOK BY SEGMENTS

- 5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
- 5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034

By Product Type

Reagents and Assays

Instruments and Platforms

Software and AI Analysis Solutions

By Biomarker Type

Genomic Biomarkers

Proteomic Biomarkers

Epigenetic Biomarkers

Transcriptomic Biomarkers

Metabolomic Biomarkers

By Technology

Next-Generation Sequencing (NGS)

Immunohistochemistry (IHC)

Mass Spectrometry (MS)-based Proteomics

Spatial Biology Platforms

Digital Pathology and AI Image Analysis

By Application

Oncology

Companion Diagnostics

Drug Discovery and Development

Neurology

Cardiovascular and Infectious Diseases

By End Use

Hospitals and Reference Labs

Pharmaceutical and Biotechnology Companies

Academic and Research Institutes

Contract Research Organizations (CROs)

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario

6.1.1. Definitions and Insights

6.1.2. Market Size Outlook to 2034

6.2. Low Growth Case Scenario

6.2.1. Definitions and Insights

6.2.2. Market Size Outlook to 2034

6.3. High Growth Case Scenario

6.3.1. Definitions and Insights

6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA NEXT GENERATION TISSUE BIOMARKERS MARKET SIZE ANALYSIS AND OUTLOOK

- 7.1. North America Next Generation Tissue Biomarkers Market Overview, 2026
- 7.2. Leading Companies Operating in North America
- 7.3. Key Industry Statistics, 2026
- 7.4. North America Next Generation Tissue Biomarkers Market Trends and Growth Opportunities to 2034
- 7.5. North America Next Generation Tissue Biomarkers Market Size Outlook by Type
- 7.6. North America Next Generation Tissue Biomarkers Market Size Outlook by Application
- 7.7. North America Next Generation Tissue Biomarkers Market Size Outlook by Country
- 7.8. United States
 - 7.8.1. Key Statistics
 - 7.8.2. The US Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 7.8.3. Key Market Drivers and Industry Developments in the US Next Generation Tissue Biomarkers Companies
- 7.9. Canada
 - 7.9.1. Key Statistics
 - 7.9.2. Canada Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 7.9.3. Key Market Drivers and Industry Developments in Canada Next Generation Tissue Biomarkers Companies
- 7.10. Mexico
 - 7.10.1. Key Statistics
 - 7.10.2. Mexico Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 7.10.3. Key Market Drivers and Industry Developments in Mexico Next Generation Tissue Biomarkers Companies

CHAPTER 8- EUROPE NEXT GENERATION TISSUE BIOMARKERS MARKET SIZE ANALYSIS AND OUTLOOK

- 8.1. Europe Next Generation Tissue Biomarkers Market Overview, 2026
- 8.2. Leading Companies Operating in Europe
- 8.3. Key Industry Statistics, 2026
- 8.4. Europe Next Generation Tissue Biomarkers Market Trends and Growth Opportunities to 2034
- 8.5. Europe Next Generation Tissue Biomarkers Market Size Outlook by Type

8.6. Europe Next Generation Tissue Biomarkers Market Size Outlook by Application

8.7. Europe Next Generation Tissue Biomarkers Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Next Generation Tissue Biomarkers Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Next Generation Tissue Biomarkers Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

8.10.3. Key Market Drivers and Industry Developments in the UK Next Generation Tissue Biomarkers Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Next Generation Tissue Biomarkers Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Next Generation Tissue Biomarkers Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Next Generation Tissue Biomarkers Companies

CHAPTER 9- ASIA PACIFIC NEXT GENERATION TISSUE BIOMARKERS MARKET SIZE ANALYSIS AND OUTLOOK

9.1. Asia Pacific Next Generation Tissue Biomarkers Market Overview, 2026

- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Next Generation Tissue Biomarkers Market Trends and Growth Opportunities to 2034
- 9.5. Asia Pacific Next Generation Tissue Biomarkers Market Size Outlook by Type
- 9.6. Asia Pacific Next Generation Tissue Biomarkers Market Size Outlook by Application
- 9.7. Asia Pacific Next Generation Tissue Biomarkers Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Next Generation Tissue Biomarkers Companies
- 9.9. Japan
 - 9.9.1. Key Statistics
 - 9.9.2. Japan Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 9.9.3. Key Market Drivers and Industry Developments in Japan Next Generation Tissue Biomarkers Companies
- 9.10. India
 - 9.10.1. Key Statistics
 - 9.10.2. India Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 9.10.3. Key Market Drivers and Industry Developments in India Next Generation Tissue Biomarkers Companies
- 9.11. South Korea
 - 9.11.1. Key Statistics
 - 9.11.2. South Korea Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 9.11.3. Key Market Drivers and Industry Developments in South Korea Next Generation Tissue Biomarkers Companies
- 9.12. Australia
 - 9.12.1. Key Statistics
 - 9.12.2. Australia Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 9.12.3. Key Market Drivers and Industry Developments in Australia Next Generation Tissue Biomarkers Companies
- 9.13. Southeast Asia
 - 9.13.1. Key Statistics
 - 9.13.2. Southeast Asia Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034
 - 9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Next

Generation Tissue Biomarkers Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA NEXT GENERATION TISSUE BIOMARKERS MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Next Generation Tissue Biomarkers Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Next Generation Tissue Biomarkers Market Trends and Growth Opportunities to 2034

10.5. South and Central America Next Generation Tissue Biomarkers Market Size Outlook by Type

10.6. South and Central America Next Generation Tissue Biomarkers Market Size Outlook by Application

10.7. South and Central America Next Generation Tissue Biomarkers Market Size Outlook by Country

10.8. Brazil

10.8.1. Key Statistics

10.8.2. Brazil Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

10.8.3. Key Market Drivers and Industry Developments in Brazil Next Generation Tissue Biomarkers Companies

10.9. Argentina

10.9.1. Key Statistics

10.9.2. Argentina Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

10.9.3. Key Market Drivers and Industry Developments in Argentina Next Generation Tissue Biomarkers Companies

10.10. Rest of Latin America

10.10.1. Key Statistics

10.10.2. Rest of Latin America Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Next Generation Tissue Biomarkers Companies

CHAPTER 11- MIDDLE EAST AND AFRICA NEXT GENERATION TISSUE BIOMARKERS MARKET SIZE ANALYSIS AND OUTLOOK

11.1. Middle East and Africa Next Generation Tissue Biomarkers Market Overview,

2026

11.2. Leading Companies Operating in Middle East and Africa

11.3. Key Industry Statistics, 2026

11.4. Middle East and Africa Next Generation Tissue Biomarkers Market Trends and Growth Opportunities to 2034

11.5. Middle East and Africa Next Generation Tissue Biomarkers Market Size Outlook by Type

11.6. Middle East and Africa Next Generation Tissue Biomarkers Market Size Outlook by Application

11.7. Middle East and Africa Next Generation Tissue Biomarkers Market Size Outlook by Country

11.8. Saudi Arabia

11.8.1. Key Statistics

11.8.2. Saudi Arabia Next Generation Tissue Biomarkers Market Size Outlook, 2021-2034

11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Next Generation Tissue Biomarkers Companies

11.9. United Arab Emirates

11.9.1. Key Statistics

11.9.2. The UAE Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

11.9.3. Key Market Drivers and Industry Developments in the UAE Next Generation Tissue Biomarkers Companies

11.10. Africa

11.10.1. Key Statistics

11.10.2. Africa Next Generation Tissue Biomarkers Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Next Generation Tissue Biomarkers Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Next Generation Tissue Biomarkers Industry

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.

Agilent Technologies Inc.

QIAGEN N.V.

Bio-Rad Laboratories Inc.

Illumina, Inc.

Laboratory Corporation of America Holdings (Labcorp)

Quest Diagnostics Incorporated

Akoya Biosciences, Inc. (Quanterix Corporation)

Bio-Techne Corporation

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Next Generation Tissue Biomarkers Market Size, Share and Growth Outlook 2026: By Product Type, By Biomarker Type, By Technology, By Application, By End Use, Companies to 2034

Product link: <https://marketpublishers.com/r/N439037F3AB4EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N439037F3AB4EN.html>